TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) announced today that an abstract for Ceplene® was presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place December 4-7, 2010, in Orlando, Florida. The Abstract, Number 2182 (Poster Board II-62) was presented today between 6:00 PM-8:00 PM in Hall A3/A4. The Abstract is entitled “Incremental Benefit of Histamine Dihydrochloride When Added to Interleukin-2 for Remission Maintenance in Acute Myeloid Leukemia: A Bayesian Meta-analysis” and was authored by Scott M. Berry, PhD and Kristine R. Broglio, MS, Berry Consultants, LLC, College Station, TX; Donald A. Berry, PhD, Berry Consultants, LLC and Division of Quantitative Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
